- Previous Close
0.00 - Open
67.50 - Bid 66.60 x --
- Ask 69.52 x --
- Day's Range
67.50 - 68.00 - 52 Week Range
59.00 - 80.00 - Volume
250 - Avg. Volume
42 - Market Cap (intraday)
60.373M - Beta (5Y Monthly) -0.23
- PE Ratio (TTM)
15.85 - EPS (TTM)
4.26 - Earnings Date Oct 18, 2024 - Oct 22, 2024
- Forward Dividend & Yield 0.50 (0.74%)
- Ex-Dividend Date Oct 5, 2023
- 1y Target Est
--
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.
www.bioqual.comRecent News: BIOQ
View MorePerformance Overview: BIOQ
Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOQ
View MoreValuation Measures
Market Cap
60.37M
Enterprise Value
71.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.82%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
58.59M
Net Income Avi to Common (ttm)
483.48k
Diluted EPS (ttm)
4.26
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--